Cargando…

Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction

Multiple categories of medications have been developed to manage lipid profiles and reduce the risk of cardiovascular events in patients with heart disease. However, currently marketed medications have not solved the problems associated with preventing and treating cardiovascular diseases completely...

Descripción completa

Detalles Bibliográficos
Autores principales:	Henry, Courtney A, Lyon, Ronald A, Ling, Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4844254/ https://www.ncbi.nlm.nih.gov/pubmed/27143910 http://dx.doi.org/10.2147/VHRM.S82387

Ejemplares similares

Efficacy and safety of different doses of evolocumab in reducing low-density lipoprotein cholesterol levels: A meta-analysis
por: Cheng, Cheng, et al.
Publicado: (2016)

Low‐density lipoprotein cholesterol lowering in real‐world patients treated with evolocumab
por: Desai, Nihar R., et al.
Publicado: (2021)

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
por: Shapiro, Michael D., et al.
Publicado: (2019)

Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study
por: Shah, Parth, et al.
Publicado: (2017)

Exploring the Efficacy of Alirocumab and Evolocumab in Reducing Low-Density Lipoprotein (LDL) Cholesterol Levels in Patients With Familial Hypercholesterolemia: A Systematic Review
por: Luthra, Gaurav, et al.
Publicado: (2022)

Effects of Evolocumab on Low‐Density Lipoprotein Cholesterol, Non–High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A Meta‐Analysis of Individual Participant Data From Double‐Blind and Open‐Label Extension Studies
por: Daviglus, Martha L., et al.
Publicado: (2020)

Effect of Evolocumab on Non‐High‐Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies
por: Toth, Peter P., et al.
Publicado: (2020)

Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
por: Katsiki, Niki, et al.
Publicado: (2023)

Clinical Significance of Electronegative Low-Density Lipoprotein Cholesterol in Atherothrombosis
por: Chu, Chih-Sheng, et al.
Publicado: (2020)

The association of financial incentives for low density lipoprotein cholesterol reduction with patient activation and motivation
por: Liu, Tianyu, et al.
Publicado: (2019)

Association of the Low-density Lipoprotein Cholesterol/High-density Lipoprotein Cholesterol Ratio with Glecaprevir-pibrentasvir Treatment
por: Akutsu, Noriyuki, et al.
Publicado: (2021)

Assessing the Accuracy of Estimated Lipoprotein(a) Cholesterol and Lipoprotein(a)‐Free Low‐Density Lipoprotein Cholesterol
por: Zheng, Weili, et al.
Publicado: (2022)

Low‐Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events
por: Willeit, Peter, et al.
Publicado: (2020)

Assessment of serum levels of triglycerides, total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol in periodontitis patients
por: Penumarthy, Swati, et al.
Publicado: (2013)

Two Patients with Familial Hypercholesterolemia Who Were Successfully Weaned from Low-density Lipoprotein Apheresis after Treatment with Evolocumab
por: Tanaka, Akihito, et al.
Publicado: (2017)

Evolocumab Effects on Lipoproteins, Measured by High-Performance Liquid Chromatography
por: Masuda, Daisaku, et al.
Publicado: (2020)

Comparison of low-density lipoprotein cholesterol/high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol for the prediction of thin-cap fibroatheroma determined by intravascular optical coherence tomography
por: WANG, Yao, et al.
Publicado: (2020)

Total cholesterol/high-density lipoprotein cholesterol and low-density lipoprotein cholesterol/high-density lipoprotein cholesterol as predictors of coronary artery calcification assessed by multidetector computed tomography coronary angiography
por: Elsadek Seaoud, Elshaimaa Aly M., et al.
Publicado: (2022)

Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD
por: Massy, Ziad A., et al.
Publicado: (2019)

Triglycerides, total cholesterol, high density lipoprotein cholesterol and low density lipoprotein cholesterol in rats exposed to premium motor spirit fumes
por: Aberare, Ogbevire L., et al.
Publicado: (2011)

Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
por: Rosenson, Robert S., et al.
Publicado: (2016)

Low Density Lipoprotein-Cholesterol/High Density Lipoprotein-Cholesterol Ratio Predicts Plaque Vulnerability in Patients With Stable Angina
por: Kim, Jeong Hun, et al.
Publicado: (2012)

Non-high density lipoprotein cholesterol versus low density lipoprotein cholesterol as a discriminating factor for myocardial infarction
por: Sigdel, Manoj, et al.
Publicado: (2012)

Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low‐Density Lipoprotein Cholesterol or Non‐High‐Density Lipoprotein Cholesterol
por: Sniderman, Allan D., et al.
Publicado: (2016)

Serum Low Density Lipoprotein Cholesterol Concentration Is Not Dependent on Cholesterol Synthesis and Absorption in Healthy Humans
por: Stellaard, Frans, et al.
Publicado: (2022)

Association of the low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio and concentrations of plasma lipids with high-density lipoprotein subclass distribution in the Chinese population
por: Tian, Li, et al.
Publicado: (2010)

Methods of Low-Density Lipoprotein-Cholesterol Measurement: Analytical and Clinical Applications
por: Islam, S.M. Touhidul, et al.
Publicado: (2022)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
por: Afanasieva, Olga, et al.
Publicado: (2020)

Of statins and low-density lipoprotein cholesterol, “fats” and fiction
por: Unnikrishnan, Ambika Gopalakrishnan, et al.
Publicado: (2016)

Visit-to-visit variability in low-density lipoprotein cholesterol
por: Sookaromdee, Pathum, et al.
Publicado: (2019)

Low-Density Lipoprotein Cholesterol Is Associated With Insulin Secretion
por: Dannecker, Corinna, et al.
Publicado: (2021)

Low-Density Lipoprotein Cholesterol and Mortality in Peritoneal Dialysis
por: Wu, Xianfeng, et al.
Publicado: (2022)

The Association between the Triglyceride to High-density Lipoprotein Cholesterol Ratio and Low-density Lipoprotein Subclasses
por: Moriyama, Kengo
Publicado: (2020)

Sofosbuvir-based direct-acting antivirals and changes in cholesterol and low density lipoprotein-cholesterol
por: Wang, Yi-Kai, et al.
Publicado: (2022)

Correlation of Friedewald's calculated low-density lipoprotein cholesterol levels with direct low-density lipoprotein cholesterol levels in a tertiary care hospital
por: Nanda, Sunil Kumar, et al.
Publicado: (2017)

Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?
por: Nurmohamed, Nick S, et al.
Publicado: (2021)

Efficacy of Evolocumab in Monogenic vs Polygenic Hypercholesterolemia
por: Lee, Timothy, et al.
Publicado: (2019)

Contribution and interaction of the low‐density lipoprotein cholesterol to high‐density lipoprotein cholesterol ratio and triglyceride to diabetes in hypertensive patients: A cross‐sectional study
por: Hong, Mengyang, et al.
Publicado: (2018)

Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol Reduction in Japanese Patients with or without Type 2 Diabetes Mellitus
por: Yamaguchi, Satoshi, et al.
Publicado: (2020)

The role of remnant cholesterol beyond low-density lipoprotein cholesterol in diabetes mellitus
por: Hu, Xiangming, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kjjo4b8mba7kr50e3q4nsoe4vk